ArticleJournal of nanobiotechnology2025
CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomedicine targeting ECM stiffness: restoring mechanical homeostasis for cancer immunotherapy.Materials today. Bio · 2026Review
- Biomimetic Cell Membrane-Based Drug Delivery Systems for Oral Diseases: Engineering Strategies, Targeting Mechanisms, and Translational Challenges.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCell membrane-camouflaged nanoparticles (NPs) have attracted increasing attention for cancer-targeted drug delivery, but their clinical translation faces critical challenges due to the biosafety concerns and scalability issues. Dermal fibroblasts are an abundant, clinically accessible membrane source, and genetic programmability offers a route to active homing.
resultsWe engineered fibroblast membrane nanovesicles from dermal fibroblasts overexpressing CXCR4 to actively home toward CXCL12-enriched tumor microenvironments. These CXCR4-engineered membrane nanovesicles demonstrated tumor-selective accumulation in multiple preclinical models with high CXCL12 secretion. The near-infrared (NIR) photosensitizer IR780 and the ferroptosis inducer RSL3 were co-loaded to form FbM@IR/RSL3 NPs for photothermal-controlled ferroptosis therapy. Upon NIR irradiation, FbM@IR/RSL3 NPs generated localized photothermal heating and simultaneously triggered RSL3 release. The combination of glutathione peroxidase 4 (GPX4) inhibition and iron-catalyzed lipid peroxidation amplified ferroptotic tumor cell death. In vivo studies reveal enhanced tumor suppression across heterogeneous carcinoma models compared to monotherapy approaches, with systemic biocompatibility confirmed by comprehensive hematological and histopathological analyses.
conclusionsFibroblast membrane engineering, combined with chemokine-gradient navigation and photothermally controlled therapeutic activation, represents the translational potential of nanomedicine in clinical by developing precision nanomedicines that coordinate biological recognition with stimulus-responsive bioactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.